Myriad Genetics and Abbott Laboratories Form Drug Discovery Collaboration

- Alliance to Focus on Discovery of Drugs to Treat Depression -

13-Mar-2002 - SALT LAKE CITY, Mar 12, 2002 Myriad Genetics, Inc., announced today that it has formed a drug discovery collaboration with Abbott Laboratories to identify novel genes and drug targets for the diagnosis and treatment of depression. The collaboration will merge Myriad's integrated drug target ...

Myriad Genetics and Biosearch Italia Form Drug Discovery Collaboration; Myriad to Screen Biosearch's

28-Nov-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN), and Biosearch Italia (Nuovo Mercato: BIO.MI) have formed a collaboration to discover novel therapeutic compounds, the Company announced today. Biosearch Italia will provide Myriad with access to its natural product compound library. Myriad will select ...

Myriad Genetics Discovers Novel Anti-Cancer Drug

11-Oct-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN) has discovered a novel drug target for the treatment of a broad range of cancers, and has initiated lead optimization with a series of compounds that selectively kill cancer cells, the Company announced today. The anti-cancer target was discovered using ...

Myriad Genetics Reports Advanced Pre-clinical Progress with Anti-HIV Drug

21-Sep-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN), today reported pre-clinical data on its lead Anti-HIV compound, MPI-49839. The drug addresses a novel mechanism in the viral-host interaction and holds the potential for an entirely new class of AIDS therapeutics. In pre-clinical tests, MPI-49839 has ...

Myriad Genetics Launches Predictive Medicine Testing in Germany, Switzerland and Austria

28-Jun-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN), has formed an exclusive collaboration with Bioscientia Ltd., an international reference laboratory company, to provide its family of BRACAnalysis® predictive medicine products in Germany, Switzerland and Austria, the Company announced today. Bioscientia, ...

Myriad Genetics Discovers High Cholesterol Gene

06-Jun-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN), has discovered a human gene responsible for high total cholesterol and low HDL (also known as "good cholesterol"), in individuals with early age myocardial infarction. The research shows that the gene's protein product is produced in abnormal amounts in ...

Myriad Genetics Drug Enters Preclinical Testing for Prevention of Acute Thrombosis

02-May-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has begun preclinical testing of its proprietary protein drug MPC-1203 for the treatment of acute thrombotic events such as those due to inflammation following major trauma, orthopedic or open heart surgery as well as for the ...

Myriad Genetics Reports Phase II Data on Lead Compound MPC-7869 at Recent Cancer Research Meeting

30-Apr-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that Phase IIa clinical trial data on its lead cancer compound, MPC-7869 was presented at the recent annual meeting of the American Association for Cancer Research. The study by lead author Michael B. Lilly, M.D. of Loma Linda University, ...

Myriad, Hitachi, Oracle and Friedli Join Forces to Map the Entire Human Proteome

05-Apr-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN), Hitachi, Ltd. (NYSE: HIT) and Oracle (Nasdaq: ORCL,) today announced that they have formed a landmark alliance to map the human proteome in less than three years. The collaboration will combine Myriad's proteomics expertise with the leading information and ...

Myriad Genetics and Syngenta Complete Rice Genome Map

29-Jan-2001 - Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has completed DNA sequencing of the entire rice genome in collaboration with the Torrey Mesa Research Institute, TMRI, (formerly Novartis Agricultural Discovery Institute, Inc.), a subsidiary of Syngenta. Myriad completed the ...